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Abstract The ability of embryonic stem (ES) cells to
generate any of the around 220 cell types of the adult
body has fascinated scientists ever since their discovery.
T h ec a p a c i t yt or e - p r o g r a mf u lly differentiated cells into
induced pluripotent stem (iPS) cells has further stimulat-
ed the interest in ES cell research. Fueled by this interest,
intense research has provided new insights into the
biology of ES cells in the recent past. The development
of large-scale and high throughput RNAi technologies
h a sm a d ei tp o s s i b l et os a m p l et h er o l eo fe v e r yg e n ei n
maintaining ES cell identity. Here, we review the RNAi
screens performed in ES cells to date and discuss the
challenges associated with these large-scale experiments.
Furthermore, we provide a perspective on how to
streamline the molecular characterization following the
initial phenotypic description utilizing bacterial artificial
chromosome (BAC) transgenesis.
Keywords RNA interference.siRNA.shRNA.esiRNA.
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TransgeneOmics
Introduction
Embryonic stem cells (ESCs) are isolated from the inner
cell mass (ICM) of mouse blastocysts [1]. Under
appropriate conditions, ES cells can be kept undifferentiated
for many passages, while maintaining their competence to
differentiate into cells of all three germ layers [2]. These
characteristics make ES cells invaluable for studying the
molecular mechanisms of pluripotency and lineage differ-
entiation processes for regenerative therapies of a variety
of human diseases [3]. With the advance of cellular
reprogramming techniques that include somatic cell
nuclear transfer (SCNT) and induced pluripotent stem
(iPS) cells, the investigation of pluripotency becomes even
more important. iPS cells are generated from somatic cells
by the forced expression of a few embryonic transcription
factors [4]. Like ES cells, iPS cells express pluripotency
markers including Oct4, Nanog and SSEA1, possess the
potential to differentiate into cells of all three germ layers,
and prominently contribute to chimeras [5]. iPS technology
holds enormous promise as it raises the prospect for the
generation of patient-specific and disease-specific stem cells,
which one day may prove useful in custom-tailored cell
therapies [reviewed in 6].
Cell fate choices in ES cells are regulated by a complex
orchestration of multiple pathways. Details regarding the
genetic and epigenetic regulations that control these
remarkable features of pluripotent cells have started to
emerge, and they include a molecular circuitry controlled
by major transcription factors, epigenetic modifications,
and post-transcriptional gene regulation [reviewed in 7].
Investigations of the interplay of transcription factors,
epigenetic regulators, and miRNAs have substantially
improved our understanding of ES cell biology. However,
recent discoveries of new pluripotency factors and path-
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network is still far from being complete [8–11].
Both gain-of-function and loss-of-function assays have
been employed to identify genes that play a role in ES cell
biology. In mammalian cells, gain-of-function screens
usually utilize libraries of pooled cDNA clones, which
require iterative rounds of selection to yield functional gene
products that are identified by clone sequencing. Genome-
wide gain-of-function screens have been successfully
performed in ESCs, and discovered novel pluripotency
genes including Nanog, Akt1 and RhoJ [2, 12]. In contrast
to the pooled cDNA libraries, recent advances of individual
arrayed cDNA libraries allow screens to be performed with
higher efficiency, complexity and sensitivity. Consequently,
several novel regulators of pluripotency including Timp2,
Hig2, and Mki67ip have recently been identified from an
arrayed cDNA library [10].
Another powerful strategy, that has been employed
extensively to investigate ES cell biology, is loss-of-
function experiments. Gene targeting via homologous
recombination [13] has been a powerful tool to generate
knock-out ES cell lines to investigate functional conse-
quences upon deletion for a number of genes [14–16].
However, the generation of targeting constructs and the
selection and validation of clones is time-consuming and
cost intensive, limiting the throughput for this approach.
RNA Interference Resources
The discovery of post-transcriptional gene silencing via RNA
interference (RNAi) allows for rapid and efficient disruption
of gene functions in cells, and has become one of the most
popular methods for loss-of-function studies. In an RNAi
reaction, the cellular RNase III enzyme Dicer cleaves the
dsRNA into 21–25 bp small interfering RNAs (siRNAs).
These siRNAs are then incorporated into the RNA-induced
silencing complex (RISC), which subsequently interacts with
the homologous mRNA in a sequence-specific manner,
resulting in the degradation of target mRNA and hence
decreased production of the corresponding protein [17].
In mammalian cells, the RNAi effect can be achieved by
direct, transient introduction of siRNAs into the cytoplasm
of cells via transfection or electroporation. siRNAs can be
generated by chemical synthesis [17], or through enzymatic
digestion of long dsRNA employing an endoribonuclease
(esiRNAs) [18]. Alternatively, the silencing triggers can be
expressed in cells as short hairpin RNAs (shRNAs), where
they are processed to siRNAs by the cellular RNAi
machinery [19].
The short nature of siRNAs allows for a flexible design
of sequences to silence the target transcript. However, the
silencing potency varies greatly between all possible
silencing triggers and each siRNA or shRNA molecule
has a different ability to silence its target transcript. To
ensure a high knockdown efficacy, algorithms have been
developed to design potent silencing triggers that are based
on the dynamic and sequence-specific properties of the
silencing molecules [20, 21]. Although the use of these
algorithms have improved the overall silencing efficacy,
typically different silencing triggers have to be experimen-
tally tested to obtain optimal knock-downs on the target
mRNA.
An evenly important desirable property of an RNAi
reagent is high target specificity. It is now well
established that siRNAs and shRNAs are silencing other
transcripts beside their intended targets. These so-called
off-target effects arise mostly from partial homologies of
the employed silencing trigger to other expressed tran-
scripts [22]. Consequently, it is possible that an observed
phenotype is not due to the knock-down of the intended
mRNA, but to the down-regulation of an off-targeted
transcript. Hence, off-target effects are a central challenge
in the RNAi field, especially for large-scale screening
experiments.
Some improvements to increase the specificity of
siRNAs and shRNAs have recently been made, for
instance by bioinformatically scanning siRNA sequences
for their potential to hybridize to 3′-UTR sequences [23].
However, an algorithm that dependably predicts off-target
signatures of silencing triggers is presently not available.
A simple approach to reduce off-target effects is pooling
of diverse siRNAs that target different regions of the same
transcript [24, 25]. The rationale for the increased
specificity via pooling is that the silencing capacities of
individual siRNAs for the intended mRNA are cumulated,
whereas off-target effects are diluted out. However, many
different siRNAs have to be pooled to obtain the most
specific results making pooling with chemically synthe-
sized siRNAs a costly effort.
Different groups have developed an alternative ap-
proach to generate complex pools of silencing triggers
for RNAi in mammalian cells [18, 26]. This technology is
based on the enzymatic digestion of long dsRNA by an
RNase III enzyme, generating heterogeneous pools of
siRNA duplexes covering a broad region (normally 300–
600 bps) of the target mRNA (Fig. 1a). The resulting
endoribonuclease-prepared siRNAs (esiRNAs) have proven
to knock down transcripts efficiently in mammalian tissue
culture cells [27], developing embryos [28] and adult mice
[29]. Their pool diversity is a distinct advantage of esiRNAs
over siRNAs or shRNAs, and explains their high degree of
target specificity (Fig. 1b), which ultimately translates into a
lower false positive rate [25, 30]. These distinct features
make esiRNA an attractive source for RNAi experiments,
especially for medium- to large-scale screens.
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the method of choice to probe gene function in mammalian
cells in general [19] and in ES cells in particular [31].
Importantly, the completion of sequenced genomes for a
variety of different organisms, including human and mouse,
has made it possible to construct genome-scale libraries of
RNAi reagents, which can be used to perform high-
throughput RNAi screens. Consequently, genome-wide
RNAi resources for siRNAs, esiRNAs and shRNAs have
been generated and employed for functional screens in a
variety of different cells [32].
RNAi Screens in ES Cells
The potential of ES cells in research and clinical applica-
tions requires a comprehensive understanding of the
pluripotency network and pathways that regulate cell fate
decisions. In the past few years, a number of RNAi screens
using shRNA, siRNA or esiRNA libraries have successfully
been performed in mouse and human ES cells [8, 9, 33–36].
The screens were performed employing different assays to
delineate genes with roles in ES cells, including cell
proliferation, cell morphology and reporter assays (Fig. 2).
Results of these screens have greatly extended our
knowledge on ES cell biology and have led to the
identification of novel components required to maintain
ES cell identity. Importantly, these screens have also
provided new insights into understanding the interplay of
multiple pathways of transcriptional factors, epigenetic
regulators and cellular signals.
Pluripotent ES cells proliferate at high rates in tissue
culture, with mouse ES cell doubling times of around 12 h
[37]. Upon differentiation these rates decrease significantly
and therefore the proliferation rate can be used to
distinguish pluripotent ES cells from cells that have exited
Fig. 1 a Scheme for the
production of endoribonuclease
prepared siRNA (esiRNA).
Important synthesis steps are
indicated. The RNase III to
cleave the dsRNA into esiRNA
is shown as triangles b
Comparison of mRNA targeting
with esiRNA and siRNA. The
regions that are targeted with
the two silencing triggers are
shown as a thick line beneath the
mRNAs. The on-target effects
are illustrated by bold arrows.
Note the additive on-target
effects of the complex pool
of esiRNA. Off-target effects
are symbolized by letters and
the size of the font represents
the prominence of the off-
target effect
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developed a fluorescence-based competition assay of
cell proliferation by mixing a fixed ratio of shRNA
transduced ES cells (GFP positive) with wild type ES
cells (GFP negative; [34]). The ratio of GFP positive
versus GFP negative cells was then monitored over time
and knockdowns that led to a decrease of GFP positive
cells were studied in detail. Using this approach ten
genes were identified that are required to maintain ES
cell identity, including known pluripotency genes
(Nanog, Oct4, Sox2), and novel factors (Tbx3, Esrrb,
Tcl1, and Dppa4). Importantly, this study established a
second, distinct pathway beside the already known Oct4,
Nanog and Sox2 pathway that is necessary for ES cell
self-renewal [34].
ES cells have a distinct morphology that distinguishes
them from other cell types. They are small with little
cytoplasm and form tightly packed colonies with round or
polygonal borders. Upon differentiation, the cells typically
get bigger and flatten out. Furthermore, they often lose the
tightly packed appearance, which leads to an extension of
the colony. These features were used by Fazzio et al. to
screen a panel of about 1000 esiRNAs targeting structural
and regulatory chromatin proteins [33]. Knockdown-
induced differentiation was then scored for defects in
viability and alterations in cell or colony morphology. 68
genes were identified that resulted in altered viability or
morphology and the Tip60-p400 complex was selected for
in-depth characterization because several components of
this complex scored in the screen and exhibited similar
differentiation phenotypes. Upon depletion of Tip60-p400,
ES cells exhibited defects in three distinguishing features:
Alkaline Phosphatase (AP) activity, EB formation and
teratoma formation. Expression profiling revealed a signif-
icant overlap between the sets of genes misregulated in
Tip60-p400 knockdown and Nanog knockdown suggesting
that Tip60-p400 functions in the same pathway as Nanog to
repress developmental genes.
Fig. 2 Summary of RNAi
screens in ES cells. Silencing
trigger delivery methods as well
as screen strategies and assay
read-outs are illustrated
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and are turned off upon differentiation of the cells. These
genes include, for instance, the pluripotency transcription
factors Oct4/Pou5f1 and Nanog. Expression of these genes
can therefore be used as a reporter for pluripotency [38].
Based on this fact, GFP reporter cell lines have been
established, where GFP is driven by promoters of pluri-
potency genes such as Oct4/Pou5f1 [39] and Nanog [40].
Consequently, these cells can be used to monitor the
pluripotency status simply by surveying GFP expression
levels [41]. Three different laboratories used this assay and
employed Oct4/Pou5f1-GFP cell lines in combination with
siRNA [8, 11] or esiRNA [9] libraries. The usage of
reporter cell lines allowed for a rapid, automated readout
and therefore all three screens were carried out as genome-
wide RNAi screens. Two of the screens were performed in
mouse ES cells [8, 9]. Although using different silencing
triggers, both screens used the same reporter cell line and a
similar strategy to monitor Oct4 expression level by FACS.
The screen by Ding et al. nominated 296 genes as primary
hits (Z-score >2), and validated 16 genes out of the top 30
primary hits (Z-score >4) using independent esiRNAs [9].
The screen by Hu et al. identified 148 genes that scored
significantly (Z score >2) as primary hits [8]. They
performed data filtering, and nominated 104 genes as
high-confidence candidates, including genes that either
scored by more than one siRNA from the primary screen,
or genes that are highly expressed in ES cells or embryonic
tissues based on published expression profiles. Although at
first glance, the overlap of the hit lists from these two
screens appears small, a second look reveals interesting
correlations between the two data sets (Fig. 3). Out of the
16 validated knockdowns from the esiRNA screen [9],
seven (44%) were also present in the 104 genes nominated
by Hu et al. Moreover, different components of an
additional four (25%) well-known protein complexes,
namely the Ccr4-Not-, Thoc-, Paf1- and Set1-complexes,
were present among the 16 validated hits, indicating that
these complexes play a role in maintaining pluripotency.
Furthermore, String analyses [42] identified interaction
partners of Ptbp1 and Ube2m to be required for ESC
identity in the list of Hu et al., suggesting potential links
of these proteins to maintain pluripotency. Hence, the
overlap of genes identified in both screens is high when
stringent validation criteria are taken into consideration.
Interestingly, in both screens Oct4 and Sox2 were
detected, whereas Nanog was not identified, indicating
that transient knockdown of Nanog did not reduce Oct4
levels significantly during the assay period.
Hu et al. selected the genes Cnot3 and Trim28 for
detailed investigations. They found that Cnot3 and Trim28
are highly expressed in ES cells and embryonic tissues and
downregulated during ES cell differentiation. Chromatin IP
experiments revealed that Cnot3 and Trim28 co-occupy
many putative gene promoters with c-Myc and Zfx, but not
other pluripotency-associated transcription factors. The
transcriptional targets of this module are enriched for genes
involved in cell cycle, cell death, and cancer. Importantly,
in their analysis only Cnot3 but not other components of
the Ccr4–Not complex were found to be required to
maintain ES cell identity, leading to the proposal that
Cnot3 action is independent of the other Cnot complex
components to maintain pluripotency. However, Ding et al.
identified and validated Cnot1 as a gene required to
maintain ES cell identity challenging the view that Cnot3
is the only Cnot complex component required to maintain
pluripotency.
Dingetal.selectedthePaf1complex (Paf1C)fora detailed
analysis. All Paf1C components were required to maintain ES
cell identity and rapid differentiation upon Paf1C depletion
was observed, activating ectodermal, mesodermal and tro-
phectodermal markers. Interestingly, knockdown of Paf1C
components did not result in activation of endodermal
markers, indicating lineage restricted differentiation upon
Paf1C depletion. The mechanism of this restricted differenti-
ation remains to be investigated. Furthermore, the study
showed that the Paf1C is enriched at promoters of pluri-
potency genes and that depletion of Paf1C results in a rapid
loss of H3K4me3 at these promoters, suggesting a link
between Paf1C and the H3K4me3 methyltransferase Set1C/
COMPASS. This link was indeed substantiated subsequently
by the finding that Paf1C interacts directly with Bre1 in H2B
ubiquitylation, which stimulates Set1C dependent H3K4 di-
and trimethylation [43].
Lastly, the first genome-wide RNAi screen in human ES
cells (hESCs) was recently published [11]. Reminiscent of
two of the mouse ES cell screens, this screen was also
performed in Oct4/Pou5f1-GFP hESCs, which express GFP
under the control of Oct4/Pou5f1 regulatory elements.
Fig. 3 Comparative analysis of validated genes required for maintai-
nance of ES cell identity from Ding et al. [9] and Hu et al. [8]. A Venn
diagram depicting the overlap, proteins that form complexes (solid
lines) and proteins that interact (dotted lines;S t r i n g8 . 3 )i ss h o w n
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primary hits were nominated in this study. Gene ontology
(GO) analysis of the primary hits showed an enrichment for
transcription factors and translation factors, including the
INO80 chromatin remodeling complex, the mediator
complex, the TAF complex, the eukaryotic initiation factor
complex, and genes that are implicated in splicing.
Substantial differences were detected when comparing the
hit list of the human ES cell screen with the four mouse
RNAi screens, suggesting that hESCs may possess diver-
gent molecular mechanisms to mouse ES cells to maintain
pluripotency. Whether this is indeed the case, or whether
the differences rather reflect different culture conditions
will have to be investigated in the future. Differences
between hES cells and mES cells have been known ever
since hES cells were first established [44]. For examples,
mES cells grow in three-dimensional, tightly packed
colonies with a population doubling time of approximately
12 h and require LIF and BMP4 growth factor signaling for
their continued self-renewal. In contrast, hES cells form
flattened two-dimensional colonies and are maintained in
bFGF and ActivinA/TGF-β to prevent differentiation.
Human ES cells proliferate slowly, with a population
doubling time averaging 36 h. Epigenetically, human and
mouse ESCs display a different pattern of X chromosome
inactivation and promoter occupancy by pluripotency
transcription factors [45].
Reports on the derivation of murine epiblast stem cells
(EpiSCs) recently provided a new perspective on the nature
of human ES cells [46, 47]. EpiSCs are derived from
postimplantation murine epiblast embryos under culture
conditions similar to hES cell culture conditions. EpiSCs
express transcription factors known to regulate pluripo-
tency, maintain their genomic integrity, and robustly
differentiate into the major somatic cell types as well as
primordial germ cells. The EpiSC lines are distinct from
mouse ES cells in their epigenetic state and the signals
controlling their differentiation. In contrast, EpiSCs dem-
onstrate striking similarities to hESCs with regard to their
molecular properties, growth factor requirements, colony
morphology, X-inactivation status, and culture dynamics
[46, 47]. These findings suggest that hES cells correspond
to cells of a postimplantation/pregastrulation stage of
mammalian development, whereas mES cells correspond
to preimplantation stages [46]. Hence, this difference may
also explain the lack of overlap of genes required to
maintain ES cell identity between the mouse- and human
ESC RNAi screens. It will therefore be interesting to
investigate the genes required to maintain EpiSCs and to
compare these genes to the list obtained in the screen with
hES cells.
Independent of the reasons for the differences in the
ES cell RNAi screens, the results show that the
regulation of pluripotency is complex and that many
factors contribute to maintain ES cell identity. The
large number of hits identified in the RNAi screens
poses a new challenge to the understanding of ES cell
biology; the detailed dissection of the molecular
mechanisms underlying the knockdown phenotypes
with current techniques will take a considerable amount
of time. Hence, strategies to streamline investigations
of identified genes in RNAi screens are desperately
needed.
TransgeneOmics
One powerful method to rapidly investigate gene func-
tion combines RNAi with bacterial artificial chromosome
(BAC) recombination technology and is called BAC
TransgeneOmics [48–50]. In TransgeneOmics a BAC
carrying a third allele of the gene of interest is introduced
and stably integrated into the genome of the host cell. To
facilitate selection and further biochemical analysis, the
BAC containing the gene of interest is modified via
homologous recombination in E. coli employing bacterio-
phage enzymes [51]. Typically, a tag that contains a
fluorescence marker (GFP) for localization studies in
addition to other features (TEV, S-peptide, PreScission,
selection marker) useful for downstream applications e.g.
affinity purification is fused during the recombination
process. Importantly, BAC recombineering is highly
efficient and can be carried out in high throughput
(Fig. 4a)[ 49].
First, a suitable BAC containing the gene of interest and
suitable primers are identified using the software BAC-
finder (www.mitocheck.org/cgi-bin/BACfinder)[ 52]. The
BAC is then typically ordered from a resource center such as
BACPAC CHORI, California, USA (http://bacpac.chori.org/),
which normally provide the plasmid as a bacterial stab
culture. The bacteria harboring the BAC are then
transduced with plasmids allowing expression of phage
recombination systems, such as the λred, or ET cloning
system [53]. The advantage of using homologous recom-
bination in E. coli for BAC modification is, that it
alleviates the limitations of the use of restriction enzymes.
Because the integration site is defined through homolo-
gous regions, which are stretches of DNA shared by the
DNA molecules that recombine, a wide range of DNA
modifications at any chosen position and unlimited by
fragment size is easily possible [53]. Because homologous
arms of only 35 to 60 nucleotides are sufficient for
successful recombination [51], they can be generated
through oligonucleotide synthesis and subsequently at-
tached to the DNA fragment via polymerase chain reaction
(PCR). This results in a linear PCR fragment, which
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increase the number of positive homologous recombination
events, an antibiotic-resistant gene (e.g. neomycin-
kanamycin) is typically included in the PCR fragment.
Therefore, bacteria carrying the inserted cassette are easily
identified through drug selection.
Correct insertion of the tagging construct is verified
by checking clones by a PCR reaction that amplifies the
region around the insertion site. Subsequently, the
purified BAC DNA is transfected into cultured mamma-
lian cells, typically through lipofection. After selection
of the marker carried on the modified BAC, cell pools
stably expressing the tagged transgene are used for
downstream analyses (see below). Because BACs are
much larger (up to 250 kb and more) than conventional
cDNA constructs and harbor the gene of interest in its
genomic context, they also frequently contain the
endogenous regulatory sequences that control the ex-
pression levels of the gene. This allows for expression
of the tagged protein at near physiological levels,
ensuring cell type-specific processing, regulation, and
splicing [49].
Streamlined Molecular Characterization of RNAi
Phenotypes through BAC Transgenesis
BAC technology offers a variety of different biochemical and
molecular biological approaches for further analysis of
candidate genes (Fig. 4b). This versatility makes the “BAC
TransgeneOmics” approach an ideal tool for studying ESC
differentiation involving different genes being expressed at
specific time points. Additionally, recombineering techni-
ques allow for the precise manipulation of BAC transgenes
by introducing specific mutations to analyze functional
consequences of mutated alleles [54]. The most straight-
forward TransgeneOmics applications are described below.
Cross-Species RNAi Rescue
As discussed above, off-target effects are frequently
observed in RNAi experiments in mammalian cells [55].
Therefore, validation of RNAi phenotypes is essential to
avoid reporting false positive results. The ultimate test of
the specificity of an RNAi experiment is a rescue
Fig. 4 a BAC transgeneOmics
pipeline. Main steps are indicated
as followed: First, a suitable BAC
clone is selected, followed by
modification using a gene-
specific BAC tagging cassette
that is inserted via homologous
recombination (BAC recombin-
eering). Finally, after transfection,
stable cell pools are selected and
investigated, b Overview of
biochemical and molecular
approaches based on BAC
TransgeneOmics
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to the silencing trigger, thus reverting the RNAi-induced
phenotype. This can be achieved by silent point mutations
introduced into cDNA constructs encoding the target gene,
such that the siRNA is no longer complementary to the
modified region [56]. However, this approach is limited by the
availability of a full-length cDNA and often requires time
consuming cloning to obtain the desired construct. Further-
more, it is very difficult to achieve endogenous expression
levels employing cDNA constructs and mis-expression of
genes can cause phenotypes by themselves.
To overcome these hurdles, a rescue approach by intro-
ducing BAC encoded orthologous genes from a closely
related species, e.g. by transfecting human genes into mouse
cells or vice versa has been established [48]. This method
achieves two things: first, the transgene is expressed at
physiological levels, because the gene is surrounded by its
own regulatory elements and second, the different DNA
sequence of the cross species gene frequently allows to
specifically silence the endogenous transcript. The cross-
species mRNAs are refractory to the silencing trigger,
therefore, abolishing the need for introducing point muta-
tions into the candidate transcript. For example, the role of
the Paf1C in the maintenance of mouse ES cell identity was
validated with this approach [9]. For this purpose, human
BACs encoding Ctr9, Rtf1, and Leo1 were engineered by
BAC TransgeneOmics [49] and stably transfected into the
mouse ES cells to render these cell lines resistant to the
corresponding esiRNAs, hence, manifesting an essential role
of the Paf1C for ESC identity [9].
Protein Localization
Determination of protein localization within cells is a vital
and frequently used method to characterize a protein of
interest including assumptions on its potential role in
protein pathways and networks. Antibodies are typically
used to investigate the localization of proteins. However,
their generation is cost-intensive and time-consuming and
the optimal staining protocol for each antibody is different
and has to be optimized. Furthermore, antibody staining
does not allow for a spatio-temporal investigation of protein
localization. The generation of BAC-tagged GFP fusion
proteins offers a versatile approach that overcomes many of
these limitations. First, cell lines expressing BAC-tagged
GFP fusion proteins can be rapidly and cost-effectively
generated. Importantly, the fusion protein is typically
expressed near physiological levels, avoiding localization
artifacts often observed when GFP-fusion proteins are over-
expressed from cDNA constructs. Second, a single, well-
defined antibody against GFP can be used employing the
same staining protocol for all tagged proteins (Fig. 5).
Third, following the GFP signal in live cells can provide
valuable spatio-temporal information of protein localization
such as protein behavior during the cell cycle or during cell
differentiation.
Proteomics
To interpret RNAi based genotype-phenotype relationships,
the identification of protein interactions is often informative.
Again antibodies are typically used to isolate proteins that
associate to the protein of interest, which are subsequently
identified via mass spectrometry [57, 58]. However, similar
restrictions as for the protein localization also apply for the
use of antibodies to investigate protein-protein interactions.
The use of generated BAC-transgenic cell lines alleviates
many of these limitations and allows for a streamlined
analysis of protein-protein interactions of large numbers of
proteins. For HeLa cells the power of this approach has
recently been demonstrated [49, 52] and is also applicable in
ES cells. For example, immunoprecipitations followed by
mass spectrometry analyses of Paf1C components identified
Wdr61 as a novel component of the Paf1C in ES cells that,
like other Paf1C components, is required to maintain ES cell
identity [9]. Because of the scalability of this approach, it
appears feasible that with TransgeneOmics a first genome-
wide ES cell proteome interaction network could be built
within the next few years.
Chromatin Immunoprecipitation
To determine the interaction sites for DNA binding proteins,
another application, chromatin immunoprecipitation (ChIP),
is highly suitable for the “BAC TransgeneOmics” approach.
Again, to avoid the reliance on specific antibodies, GFP-
tagged BAC transgenes can be used in ChIP employing a
standardized assay, eliminating the need to establish the best
protocol for a given antibody. Importantly, large-scale ChIP
applications,suchasChIP-chipandChIP-seqarealsofeasible
with the BAC TransgeneOmics approach. Employing this
technology it was demonstrated that the Paf1C component
Ctr9isenrichedatcertainpromotersinEScells,particularlyat
promoters of pluripotency genes [9]. Scaling of this approach
promises to deliver high quality data of genome binding sites
for many DNA binding proteins, which should help to
decipher chromosome organization and transcription factor
networks in ES cells.
Perspective
Through the development of RNAi technologies in ES cells
we have witnessed a dramatic extension of our knowledge
about these cells. Different assays to identify genes with
roles in ES cell biology have been employed in a variety of
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genes required to maintain ES cell identity. These experi-
ments have also allowed a first glimpse of the complexity
to maintain a balance between pluripotency and the
capacity for rapid differentiation in these cells. However,
these results have also shown us that we are only beginning
to understand ES cell biology at a systems level and that
many more assays are required to obtain a comprehensive
list of the genes that play a role to maintaining ES cell
identity. A focus to identify novel factors has so far relied
on Oct4/Pou5f1 as a reporter for pluripotency. It will be
interesting to employ other pluripotency reporter cell lines
(e.g. Nanog, Rex1 etc.) in equivalent assays to search for
additional factors that have an impact on ES cells. In a
slight modification, reporter cell lines for lineage markers
should also prove valuable to search for genes that are
implicated in the differentiation into certain lineages. In this
scenario, undifferentiated ES cells would not be fluorescent
and the number of differentiated cells for a particular
lineage (e.g. Cdx1-GFP for trophectoderm, or brachyury-
GFP for mesoderm etc.) could be scored after each
knockdown by counting the percent of GFP positive cells.
This study would not only provide novel insight into ES
cell biology but could also improve protocols to differen-
tiate ES cells selectively into defined lineages.
The identification of genes implicated in ES cell
identity is a prerequisite to understand ES cells at a
systems level. However, the mere identification and
phenotypic description upon depletion will not be
sufficient to understand the function of each gene
mechanistically. The TransgeneOmics approach is suit-
able to obtain a deeper mechanistic insight into the
molecular reasons underlying the depletion phenotypes.
It is scaleable and possible to perform in high-
throughput, promising to rapidly deliver the necessary
information to build meaningful mathematical models of
pluripotency. Hence, the generation of a repository of
BAC-tagged ES cells should be a useful resource for the
scientific community. Importantly, this resource could be
the starting point to perform the described experiments
not only in ES cells but also in any other cell type of the
body, because animals could be generated from these
cells [49], promising to further accelerate gene function
studies in the future.
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